ALLO has 36-month beta value of 0.31. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ALLO is 149.47M, and currently, short sellers hold a 18.31% ratio of that float. The average trading volume of ALLO on June 03, 2025 was 3.37M shares.
ALLO) stock’s latest price update
Allogene Therapeutics Inc (NASDAQ: ALLO)’s stock price has increased by 8.55 compared to its previous closing price of 1.17. However, the company has seen a 19.81% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-01 that SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells.
ALLO’s Market Performance
Allogene Therapeutics Inc (ALLO) has experienced a 19.81% rise in stock performance for the past week, with a -24.85% drop in the past month, and a -29.44% drop in the past quarter. The volatility ratio for the week is 3.81%, and the volatility levels for the past 30 days are at 8.13% for ALLO. The simple moving average for the last 20 days is 9.28% for ALLO stock, with a simple moving average of -39.00% for the last 200 days.
Analysts’ Opinion of ALLO
Citizens JMP, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $5. The rating they have provided for ALLO stocks is “Mkt Outperform” according to the report published on March 14th, 2025.
Oppenheimer gave a rating of “Outperform” to ALLO, setting the target price at $11 in the report published on August 08th of the previous year.
ALLO Trading at -7.44% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.40% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Yoshiyama Annie, who sale 9,601 shares at the price of $1.41 back on Apr 21 ’25. After this action, Yoshiyama Annie now owns 130,663 shares of Allogene Therapeutics Inc, valued at $13,537 using the latest closing price.
Yoshiyama Annie, the Officer of Allogene Therapeutics Inc, proposed sale 9,601 shares at $1.41 during a trade that took place back on Apr 21 ’25, which means that Yoshiyama Annie is holding shares at $13,537 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- 12222.09 for the present operating margin
- 1.0 for the gross margin
The net margin for Allogene Therapeutics Inc stands at 11469.23. The total capital return value is set at -0.56. Equity return is now at value -59.60, with -46.11 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -812.34.
Currently, EBITDA for the company is -243.33 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of -14392.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.71.
Conclusion
To put it simply, Allogene Therapeutics Inc (ALLO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
